Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$3.35
-28.4%
$1.85
$0.40
$5.48
$56.89M0.37349,340 shs1.43 million shs
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$0.80
+1.6%
$0.69
$0.45
$1.99
$59.98M1.43403,210 shs115,807 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.77
$1.85
$0.89
$3.19
$53.00M0.12295,588 shs320,322 shs
23andMe Holding Co. stock logo
ME
23andMe
$0.50
-35.3%
$0.50
$0.53
$10.81
$13.36M1.191.49 million shs29.28 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-1.27%+50.97%+188.89%+345.71%+513.61%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
+6.86%+13.19%+22.97%+8.97%-15.77%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
+5.36%+8.26%-7.33%+12.03%+50.00%
23andMe Holding Co. stock logo
ME
23andMe
0.00%0.00%0.00%0.00%-94.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.4805 of 5 stars
0.03.00.00.02.50.80.0
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
4.066 of 5 stars
3.52.00.04.72.40.80.6
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.8175 of 5 stars
3.65.00.00.01.90.00.6
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
0.00
N/AN/AN/A
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
3.00
Buy$3.00280.71% Upside
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.17
Buy$8.20360.67% Upside
23andMe Holding Co. stock logo
ME
23andMe
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ME, ABVC, CUE, and GANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
5/19/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
$508.38K112.57N/AN/A$0.06 per share56.17
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$7.99M7.43N/AN/A$0.28 per share2.81
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/A$0.28 per shareN/A
23andMe Holding Co. stock logo
ME
23andMe
$208.78M0.06$0.54 per share0.93$2.34 per share0.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
-$4.90M-$0.13N/AN/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$40.67M-$0.67N/AN/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)
23andMe Holding Co. stock logo
ME
23andMe
-$666.70M-$15.45N/AN/A-183.39%-170.07%-62.13%N/A

Latest ME, ABVC, CUE, and GANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.16-$0.16N/A-$0.16$0.03 millionN/A
5/12/2025Q1 2025
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million
4/30/2025Q4 2024
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A-$0.06N/A-$0.06N/AN/A
4/15/2025Q4 2024
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A$0.04N/A$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/AN/AN/AN/AN/A
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
N/A
0.22
0.22
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.03
1.03
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.05
2.22
2.22
23andMe Holding Co. stock logo
ME
23andMe
N/A
1.05
0.91

Institutional Ownership

CompanyInstitutional Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
11.38%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
23andMe Holding Co. stock logo
ME
23andMe
36.10%

Insider Ownership

CompanyInsider Ownership
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
17.10%
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
10.78%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
23andMe Holding Co. stock logo
ME
23andMe
26.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
ABVC BioPharma, Inc. stock logo
ABVC
ABVC BioPharma
3016.98 million14.08 millionNot Optionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
6075.35 million67.23 millionOptionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2029.95 million27.80 millionOptionable
23andMe Holding Co. stock logo
ME
23andMe
77026.83 million19.77 millionNot Optionable

Recent News About These Companies

23andMe Privacy Reviewer Defends WilmerHale as Choice of Counsel
23andMe Judge Denies California Bid to Pause State Data Transfer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ABVC BioPharma stock logo

ABVC BioPharma NASDAQ:ABVC

$3.35 -1.33 (-28.42%)
Closing price 04:00 PM Eastern
Extended Trading
$3.34 0.00 (-0.15%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$0.80 +0.01 (+1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$0.77 -0.03 (-3.14%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.77 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.83 +0.06 (+3.39%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

23andMe stock logo

23andMe NASDAQ:ME

$0.50 -0.27 (-35.32%)
Closing price 03/28/2025
Extended Trading
$0.50 0.00 (0.00%)
As of 03/28/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.